{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T20:26:44Z","timestamp":1787344004397,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12640-x","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T07:15:38Z","timestamp":1787296538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic landscape of ERCC alterations in breast and gynecological cancers: implications for targeted therapy and VUS reclassification"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9516-0047","authenticated-orcid":false,"given":"Sezin","family":"Canbek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3775-4388","authenticated-orcid":false,"given":"Melisa","family":"Karaa\u011fa\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0952-601X","authenticated-orcid":false,"given":"Aleyna","family":"Ermi\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5858-0039","authenticated-orcid":false,"given":"\u015eeref","family":"T\u00fcrkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6782-2373","authenticated-orcid":false,"given":"Cumhur Sel\u00e7uk","family":"Topal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-9284","authenticated-orcid":false,"given":"Nurullah","family":"\u0130lhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-0838","authenticated-orcid":false,"given":"Cem","family":"Yal\u00e7\u0131nkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-3822","authenticated-orcid":false,"given":"Fikret","family":"Ezberci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"12640_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"JM Kocarnik","year":"2022","unstructured":"Kocarnik JM, Compton K, Dean FE et al (2022) Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol 8:420\u2013444","journal-title":"JAMA Oncol"},{"key":"12640_CR2","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1038\/s41467-018-05467-z","volume":"9","author":"S Wu","year":"2018","unstructured":"Wu S, Zhu W, Thompson P, Hannun YA (2018) Evaluating intrinsic and non-intrinsic cancer risk factors. Nat Commun 9:3490","journal-title":"Nat Commun"},{"key":"12640_CR3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41586-020-03147-x","volume":"590","author":"D Alonso-Curbelo","year":"2021","unstructured":"Alonso-Curbelo D, Ho YJ, Burdziak C et al (2021) A gene\u2013environment-induced epigenetic program initiates tumorigenesis. Nature 590:642\u2013648","journal-title":"Nature"},{"key":"12640_CR4","doi-asserted-by":"publisher","first-page":"629266","DOI":"10.3389\/fphar.2020.629266","volume":"11","author":"LY Li","year":"2021","unstructured":"Li LY, Guan YD, Chen XS, Yang JM, Cheng Y (2021) DNA repair pathways in cancer therapy and resistance. Front Pharmacol 11:629266","journal-title":"Front Pharmacol"},{"key":"12640_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrm3822","volume":"15","author":"JA Marteijn","year":"2014","unstructured":"Marteijn JA, Lans H, Vermeulen W, Hoeijmakers JH (2014) Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol 15:465\u2013481","journal-title":"Nat Rev Mol Cell Biol"},{"key":"12640_CR6","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3390\/ijms21030870","volume":"21","author":"S Pietrasik","year":"2020","unstructured":"Pietrasik S, Zajac G, Morawiec J, Soszynski M, Fila M, Blasiak J (2020) Interplay between BRCA1 and GADD45A and its potential for nucleotide excision repair in breast cancer pathogenesis. Int J Mol Sci 21:870","journal-title":"Int J Mol Sci"},{"key":"12640_CR7","doi-asserted-by":"publisher","first-page":"e6832","DOI":"10.1097\/MD.0000000000006832","volume":"96","author":"T Qian","year":"2017","unstructured":"Qian T, Zhang B, Qian C, He Y, Li Y (2017) Association between common polymorphisms in ERCC gene and glioma risk: a meta-analysis of 15 studies. Medicine 96:e6832","journal-title":"Medicine"},{"key":"12640_CR8","doi-asserted-by":"publisher","first-page":"13925","DOI":"10.1038\/s41598-023-40185-7","volume":"13","author":"C Chen","year":"2023","unstructured":"Chen C, Liu H, Li Y, Liu J (2023) Association of ERCC family mutations with prognosis and immune checkpoint inhibitors response in multiple cancers. Sci Rep 13:13925","journal-title":"Sci Rep"},{"key":"12640_CR9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3389\/fonc.2020.01167","volume":"10","author":"MM Aiello","year":"2020","unstructured":"Aiello MM, Solinas C, Santoni M et al (2020) Excision repair cross complementation group 1 single nucleotide polymorphisms and nivolumab in advanced non-small cell lung cancer. Front Oncol 10:1167","journal-title":"Front Oncol"},{"key":"12640_CR10","doi-asserted-by":"publisher","first-page":"153303382199004","DOI":"10.1177\/1533033821990046","volume":"20","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Fu Y, Wen L, Deng Y, Chen J, Liu K (2021) XPD Polymorphisms and risk of hepatocellular carcinoma and gastric cancer: A Meta-Analysis. Technol Cancer Res Treat 20:1533033821990046","journal-title":"Technol Cancer Res Treat"},{"key":"12640_CR11","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.7150\/jca.54576","volume":"12","author":"S Wang","year":"2021","unstructured":"Wang S, Liu W, Ni Y et al (2021) Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer. J Cancer 12:2550","journal-title":"J Cancer"},{"key":"12640_CR12","doi-asserted-by":"publisher","first-page":"951193","DOI":"10.3389\/fonc.2022.951193","volume":"12","author":"C Zuo","year":"2022","unstructured":"Zuo C, Lv X, Liu T et al (2022) Polymorphisms in ERCC4 and ERCC5 and risk of cancers: Systematic research synopsis, meta-analysis, and epidemiological evidence. Front Oncol 12:951193","journal-title":"Front Oncol"},{"key":"12640_CR13","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/1878-0261.12965","volume":"15","author":"R Sreekumar","year":"2021","unstructured":"Sreekumar R, Al-Saihati H, Emaduddin M et al (2021) The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer. Mol Oncol 15:2065\u20132083","journal-title":"Mol Oncol"},{"key":"12640_CR14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4103\/IJPM.IJPM_964_19","volume":"63","author":"MA Tejasvi","year":"2020","unstructured":"Tejasvi MA, Maragathavalli G, Putcha UK, Ramakrishna M, Vijayaraghavan R, Avinash CA (2020) Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. Indian J Pathol Microbiol 63:538\u2013543","journal-title":"Indian J Pathol Microbiol"},{"key":"12640_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/jcpt.13166","volume":"45","author":"A Varma","year":"2020","unstructured":"Varma A, Mathaiyan J, Shewade D, Dubashi B, Sunitha K (2020) Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India. J Clin Pharm Ther 45:617\u2013627","journal-title":"J Clin Pharm Ther"},{"key":"12640_CR16","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.3390\/biomedicines11123133","volume":"11","author":"T Zou","year":"2023","unstructured":"Zou T, Liu JY, Qin Q et al (2023) Role of rs873601 polymorphisms in prognosis of lung cancer patients treated with platinum-based chemotherapy. Biomedicines 11:3133","journal-title":"Biomedicines"},{"key":"12640_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/emm.2005.12","volume":"37","author":"SA Lee","year":"2005","unstructured":"Lee SA, Lee KM, Park WY et al (2005) Obesity and genetic polymorphism of ERCC2 and ERCC4 as modifiers of risk of breast cancer. Exp Mol Med 37:86\u201390","journal-title":"Exp Mol Med"},{"key":"12640_CR18","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s11033-021-06994-7","volume":"49","author":"SA Sahaba","year":"2022","unstructured":"Sahaba SA, Rashid MA, Islam MS et al (2022) The link of ERCC2 rs13181 and ERCC4 rs2276466 polymorphisms with breast cancer in the Bangladeshi population. Mol Biol Rep 49:1847\u20131856","journal-title":"Mol Biol Rep"},{"key":"12640_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/2159-8290.CD-16-0487","volume":"6","author":"J Vijai","year":"2016","unstructured":"Vijai J, Topka S, Villano D et al (2016) A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer. Cancer Discov 6:1267\u20131275","journal-title":"Cancer Discov"},{"key":"12640_CR20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/cancers11081149","volume":"11","author":"TM Abdel-Fatah","year":"2019","unstructured":"Abdel-Fatah TM, Ali R, Sadiq M et al (2019) ERCC1 is a predictor of anthracycline resistance and taxane sensitivity in early stage or locally advanced breast cancers. Cancers 11:1149","journal-title":"Cancers"},{"key":"12640_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-015-1053-0","volume":"4","author":"A Dumont","year":"2015","unstructured":"Dumont A, Pannier D, Ducoulombier A et al (2015) ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors. Springerplus 4:1\u201310","journal-title":"Springerplus"},{"key":"12640_CR22","first-page":"2934","volume":"8","author":"J Lu","year":"2015","unstructured":"Lu J, Zhao H, Li S, Tian Z, Zhu X, Wang H, Fu H (2015) Correlation of rs1799793 polymorphism in ERCC2 and the clinical response to platinum-based chemotherapy in patients with triple negative breast cancer. Int J Clin Exp Med 8:2934","journal-title":"Int J Clin Exp Med"},{"key":"12640_CR23","doi-asserted-by":"publisher","first-page":"gkaf1303","DOI":"10.1093\/nar\/gkaf1303","volume":"53","author":"M Robu","year":"2025","unstructured":"Robu M, van den Shah RG et al (2025) PARP1 and PARylation facilitate transcription-coupled DNA repair by stabilizing the CSB-RNAPII complex. Nucleic Acids Res 53:gkaf1303","journal-title":"Nucleic Acids Res"},{"key":"12640_CR24","doi-asserted-by":"publisher","first-page":"e70208","DOI":"10.1111\/cbdd.70208","volume":"106","author":"MB Shahsavani","year":"2025","unstructured":"Shahsavani MB, Heidari M, Yousefi R, Moosavi-Movahedi AA (2025) Platinum-Based Chemotherapeutics in the Modern Era: From Classical DNA-Targeting Mechanisms to Next-Generation Innovations in Cancer Therapy. Chem Biol Drug Des 106:e70208","journal-title":"Chem Biol Drug Des"},{"key":"12640_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"DA Levine","year":"2013","unstructured":"Levine DA et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67\u201373","journal-title":"Nature"},{"key":"12640_CR26","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.32604\/or.2025.063951","volume":"33","author":"R G\u00f3mez-Molina","year":"2025","unstructured":"G\u00f3mez-Molina R, Mart\u00ednez R, Su\u00e1rez M, Pe\u00f1a-Cabia A, Calder\u00f3n MC et al (2025) Lynch syndrome and colorectal cancer: A review of current perspectives in molecular genetics and clinical strategies. Oncol Res 33:1531\u20131545","journal-title":"Oncol Res"},{"key":"12640_CR27","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.3390\/cancers18152526","volume":"18","author":"CM Macrea","year":"2026","unstructured":"Macrea CM, Ilias T, Costea A, Trif P, Murvai VR, Fratila OC (2026) The Genetic Landscape of Colorectal Cancer: From Molecular Alterations to Therapeutic Decision Pathways. Cancers 18:2526","journal-title":"Cancers"},{"key":"12640_CR28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3390\/cancers12071713","volume":"12","author":"K Tomasova","year":"2020","unstructured":"Tomasova K, Cumova A, Seborova K et al (2020) DNA repair and ovarian carcinogenesis: impact on risk, prognosis and therapy outcome. Cancers 12:1713","journal-title":"Cancers"},{"key":"12640_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.09.023","volume":"141","author":"A Stradella","year":"2020","unstructured":"Stradella A, Del Valle J, Rofes P et al (2020) ERCC3, a new ovarian cancer susceptibility gene? Eur J Cancer 141:1\u20138","journal-title":"Eur J Cancer"},{"key":"12640_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2741\/4230","volume":"19","author":"A Paul","year":"2014","unstructured":"Paul A, Paul S (2014) The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Front Biosci 19:605","journal-title":"Front Biosci"},{"key":"12640_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-017-0195-9","volume":"15","author":"S Bhattacharjee","year":"2017","unstructured":"Bhattacharjee S, Nandi S (2017) DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway. Cell Commun Signal 15:1\u201310","journal-title":"Cell Commun Signal"},{"key":"12640_CR32","doi-asserted-by":"crossref","unstructured":"Chen J, Sun N, Hu G et al (2017) Association of ERCC1 polymorphisms with the risk of colorectal cancer: a meta-analysis. Crit Rev Eukaryot Gene Expr 27","DOI":"10.1615\/CritRevEukaryotGeneExpr.2017019713"},{"key":"12640_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrm.2016.48","volume":"17","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi R, Sarangi P, D\u2019Andrea AD (2016) The Fanconi anaemia pathway: new players and new functions. Nat Rev Mol Cell Biol 17:337\u2013349","journal-title":"Nat Rev Mol Cell Biol"},{"key":"12640_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609","journal-title":"Nature"},{"key":"12640_CR35","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/jnci\/92.11.874","volume":"92","author":"M Berwick","year":"2000","unstructured":"Berwick M, Vineis P (2000) Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 92:874\u2013897","journal-title":"J Natl Cancer Inst"},{"key":"12640_CR36","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1038\/onc.2011.611","volume":"31","author":"C Zeller","year":"2012","unstructured":"Zeller C, Dai W, Steele NL et al (2012) Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31:4567\u20134576","journal-title":"Oncogene"},{"key":"12640_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature16166","volume":"529","author":"S Wu","year":"2016","unstructured":"Wu S, Powers S, Zhu W, Hannun YA (2016) Substantial contribution of extrinsic risk factors to cancer development. Nature 529:43\u201347","journal-title":"Nature"},{"key":"12640_CR38","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature14184","volume":"518","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi R, Liu JC, Amunugama R et al (2015) Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair. Nature 518:258\u2013262","journal-title":"Nature"},{"key":"12640_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.gde.2008.01.016","volume":"18","author":"SA Martin","year":"2008","unstructured":"Martin SA, Lord CJ, Ashworth A (2008) DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 18:80\u201386","journal-title":"Curr Opin Genet Dev"},{"key":"12640_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/path.2631","volume":"220","author":"SA Martin","year":"2010","unstructured":"Martin SA, Hewish M, Lord CJ, Ashworth A (2010) Genomic instability and the selection of treatments for cancer. J Pathol 220:281\u2013289","journal-title":"J Pathol"},{"key":"12640_CR41","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/jnci\/84.19.1512","volume":"84","author":"M Dabholkar","year":"1992","unstructured":"Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512\u20131517","journal-title":"J Natl Cancer Inst"},{"key":"12640_CR42","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1093\/annonc\/mdt238","volume":"24","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Boku N, Nishina T et al (2013) Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer. Ann Oncol 24:2560\u20132565","journal-title":"Ann Oncol"},{"key":"12640_CR43","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.ajhg.2012.02.027","volume":"90","author":"D Park","year":"2012","unstructured":"Park D, Lesueur F, Nguyen-Dumont T et al (2012) Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 90:734\u2013739","journal-title":"Am J Hum Genet"},{"key":"12640_CR44","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/pharmaceutics16091121","volume":"16","author":"A Barba","year":"2024","unstructured":"Barba A, L\u00f3pez-Vilar\u00f3 L, Ferre M et al (2024) ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer. Pharmaceutics 16:1121","journal-title":"Pharmaceutics"},{"key":"12640_CR45","doi-asserted-by":"publisher","first-page":"e85448","DOI":"10.1371\/journal.pone.0085448","volume":"9","author":"B Salhia","year":"2014","unstructured":"Salhia B, Kiefer J, Ross JT et al (2014) Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS ONE 9:e85448","journal-title":"PLoS ONE"},{"key":"12640_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","volume":"26","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi R, Rondinelli B, D\u2019Andrea AD (2016) Repair pathway choices and consequences at the double-strand break. Trends Cell Biol 26:52\u201364","journal-title":"Trends Cell Biol"},{"key":"12640_CR47","doi-asserted-by":"publisher","first-page":"e1006248","DOI":"10.1371\/journal.pgen.1006248","volume":"12","author":"A Rump","year":"2016","unstructured":"Rump A, Benet-Pages A, Schubert S et al (2016) Identification and functional testing of ERCC2 mutations in a multi-national cohort of patients with familial breast-and ovarian cancer. PLoS Genet 12:e1006248","journal-title":"PLoS Genet"},{"key":"12640_CR48","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pharmthera.2012.10.009","volume":"137","author":"JM Furgason","year":"2013","unstructured":"Furgason JM, Bahassi EM (2013) Targeting DNA repair mechanisms in cancer. Pharmacol Ther 137:298\u2013308","journal-title":"Pharmacol Ther"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12640-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12640-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12640-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T20:02:27Z","timestamp":1787342547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12640-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12640"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12640-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We have no declaration of interest on this research as authors.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1440"}}